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Abstract
Introduction Cardiac operations account for a large pro-
portion of the blood transfusions given each year, leading
to high costs and an increased risk to patient safety. There-
fore, it is important to explore initiatives to reduce trans-
fusion rates. This study aims to provide a benchmark for
transfusion practice by inter-hospital comparison of trans-
fusion rates, blood product use and costs related to patients
undergoing coronary artery bypass grafting (CABG), valve
surgery or combined CABG and valve surgery.
Methods Between 2010 and 2013, patients from four Dutch
hospitals undergoing CABG, valve surgery or combined
CABG and valve surgery (n = 11,150) were included by
means of a retrospective longitudinal study design.
Results In CABG surgery the transfusion rate ranged be-
tween 43 and 54%, in valve surgery between 54 and 67%,
and in combined CABG and valve surgery between 80 and
88%. With the exception of one hospital, the trend in trans-
 C. Brouwers
c.brouwers@vumc.nl
1 EMGO+ Institute for Health and Care Research, Department
of Public and Occupational Health, VU University Medical
Center, Amsterdam, The Netherlands
2 Department of Cardiothoracic Surgery, VU University
Medical Center, Amsterdam, The Netherlands
3 Department of Cardiothoracic Surgery, Onze Lieve Vrouwe
Gasthuis, Amsterdam, The Netherlands
4 Department of Cardiothoracic Surgery, Academic Medical
Center, Amsterdam, The Netherlands
5 Department of Anesthesiology and Intensive Care, St.
Antonius Hospital, Nieuwegein, The Netherlands
6 Netherlands institute for health services research (NIVEL),
Utrecht, The Netherlands
fusion rate showed a significant decrease over time for all
procedures. Hospitals differed significantly in the units of
blood products given to each patient, and in the use of spe-
cific transfused combinations of blood products, such as
red blood cells (RBCs) and a combination of RBCs, fresh
frozen plasma (FFP) and platelets.
Conclusion This study indicates that benchmarking blood
product usage stimulates awareness of transfusion be-
haviour, which may lead to better patient safety and lower
costs. Further studies are warranted to improve awareness
of transfusion behaviour and increase the standardisation
of transfusion practice in cardiac surgery.
Keywords Cardiac surgery · CABG · Valve · Blood
transfusion · Blood products · Benchmark
Introduction
The use of transfused blood products is disproportionately
distributed among hospitalised patients, whereby a minor-
ity of patients consume the majority of transfused blood
products [1]. Patients undergoing cardiac procedures are
more likely to receive transfused blood products because of
the high risk of blood loss and severe anaemia [2]. Clinical
guidelines regarding the use of blood products in cardiac
surgery have been available since the mid-1980s and sup-
port surgeons in their choice for blood transfusion by pro-
viding recommendations regarding preoperative risk man-
agement, perioperative blood conservation, and the man-
agement of blood resources [1, 3, 4].
However, despite these guidelines there is a great vari-
ability in the use of blood products between countries,
institutions and practitioners in cardiac surgery, which are
caused by differences in human, technical and organisa-
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tional-related factors [5, 6]. One way of examining the
differences in these factors between hospitals is by bench-
marking. Benchmarking is the process of establishing
a standard of excellence by comparing a particular activity
and its outcomes in one organisation with the same activity
in another organisation [7].
This study aims to provide a benchmark for transfusion
practice by comparing transfusion rates, blood product use
and costs in patients undergoing coronary artery bypass
grafting (CABG), valve surgery or combined CABG and
valve surgery between hospitals.
Materials and methods
Study setting and population
This retrospective longitudinal study was carried out in two
academic hospitals and two non-academic top clinical cen-
tres in the Netherlands. Hospital data on all patients under-
going CABG, valve surgery or combined CABG and valve
surgery between 2010 and 2013 was obtained from each
hospital. Patients under 18 years of age, patients admit-
ted before or after the study period, patients whose period
of hospitalisation overlapped two calendar years, and pa-
tients undergoing CABG or valve surgery in combination
with complex cardiothoracic surgery were excluded from
the study.
The data for this study were not collected simultaneously,
instead we collected the data in three steps: in 2011 we
collected the data from 2010, in 2012 we collected the
data from 2011, and in 2014 we collected the data from
2012 and 2013. After each round of data collection, the
hospitals received a report in which the transfusion rates and
costs between the hospitals were compared. In addition, in
May 2012 and September 2013 benchmark meetings were
organised which were attended by representatives from each
hospital who were involved in blood transfusion practice in
cardiac surgery patients. At these meetings, the results of
the report were discussed in order to share experiences,
create awareness, and to stipulate reduction strategies for
the coming year.
This study was approved by the medical ethics commit-
tee of the VU University Medical Center, Amsterdam.
Data collection
Data on sex, age, type of surgery (CABG or valve surgery),
blood product use for each patient throughout the hospi-
tal admission period (none, red blood cells (RBCs), fresh
frozen plasma (FFP) or platelets), length of hospital stay (in
days), and haemoglobin (i. e. preoperative Hb, lowest in-
traoperative Hb and postoperative Hb) were collected using
the electronic health record system of the hospitals. Data
on blood loss was collected using the clinical ward system
of cardiothoracic surgery. Blood loss was defined as chest
tube blood loss at 24 h postoperatively.
Costs
The costs of blood products were based on the average cost
price per unit from Sanquin Blood Supply between 2010
and 2013. These were C 216.50 for RBCs, C 185.70 for
FFP and C 521.90 for platelets. The platelet product used
for the cost calculation is composed of five buffy coats of
identical ABO and Rh(D) compatible blood groups, mixed
with plasma or platelet storage solution.
Data analysis
To compare the demographic and clinical characteristics of
the patients in each hospital, one-way ANOVA, Kruskal-
Wallis tests, or Chi-squared tests were used depending on
the measurement and variable distribution. Chi-squared
tests were also used to examine the differences in trans-
fusion rates over time and between hospitals. Transfusion
rates were defined as the proportion of patients receiving
any transfusion with packed RBCs, FFP and/or platelets.
Combinations of transfused blood products were defined
as the percentage of patients receiving at least one unit of
RBCs, FFP or platelets, or a combination of these types of
blood product.
A logistic regression analysis was performed to investi-
gate the predictors of blood transfusion. The following co-
variates were selected for inclusion in the regression analy-
sis: hospital (A–D), age during hospitalisation, blood loss at
24 h, type of surgery (CABG, valve, CABG + valve), total
duration of hospitalisation, and haemoglobin levels before
surgery. All these variables were entered into the logistic
regression model simultaneously using the enter method.
Missing value analysis showed that hospital D had no data
on blood loss at 24 h in 2011. Hence, the patients from hos-
pital D from 2011 were excluded from the analyses. For
the other variables only a small percentage of values (5%)
was missing at random.
The mean costs of transfused blood products per cardio-
thoracic surgical procedure were calculated by multiplying
cost prices by the mean number of units transfused (based
on both transfused and non-transfused patients). The dif-
ference in costs between hospitals were calculated using
a one-way ANOVA. A sensitivity analysis showed no dif-
ference in results between the one-way ANOVA with and
without bootstrapping (using 1000 bootstrap samples). The
maximum cost difference for each cardiothoracic surgical
procedure between the hospitals was calculated by subtract-
ing the lowest mean costs from the highest mean costs. A p-
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Table 1 Patient demographics and surgical characteristics (2010–2013)
Hospital A Hospital B Hospital C Hospital Da p-value
N 2356 2610 2382 3802
Males (%) 75% 71% 71% 70% <0.001
Age (years) 67.3 ± 10.1 67.4 ± 9.9 66.6 ± 11.3 67.3 ± 10.6 0.019
Type of surgery <0.001
CABG [n] 1516 1427 1291 2125
Valve surgery [n] 512 723 736 1175
CABG + valve surgery [n] 328 460 355 502
Type of valve surgery <0.001
Aortic valve replacement [n] 454 681 681 962
Mitral valve repair [n] 131 225 107 550
Other [n] 464 49 101 10
Multiple valves [n] 395 217 202 155
Preoperative Hb (mmol/l) 8.6 ± 1.0 8.0 ± 1.1 8.3 ± 1.2 8.3 ± 1.1 <0.001
Lowest intraoperative Hb (mmol/l) 6.5 ± 0.9 5.2 ± 0.8 5.1 ± 1.1 – <0.001
Discharge Hb (mmol/l) 7.0 ± 0.9 6.6 ± 0.9 6.4 ± 0.8 6.7 ± 0.9 <0.001
24-hour blood loss (ml)
CABG 486 (295–560) 415 (310–610) 800 (575–1150) 710 (540–940) <0.001
Valve surgery 315 (225–490) 355 (250–575) 550 (360–830) 600 (400–920) <0.001
CABG + valve surgery 495 (350–781) 535 (360–802) 900 (610–1305) 1175 (800–1750) <0.001
Hospital length of stay (days) 10.3 ± 9.1 11.6 ± 9.1 10.8 ± 9.0 10.7 ± 8.8 <0.001
Postoperative length of stay (days) 6.8 ± 8.7 7.8 ± 6.4 7.1 ± 5.5 7.7 ± 7.0 0.001
aHospital D has missing data on 2011
CABG coronary artery bypass graft, Hb haemoglobin
value of <0.05 was considered to be statistically significant.
The data were analysed with SPSS version 20.0 software
(IBM, New York, USA).
Results
Patient characteristics
The total number of patients undergoing CABG, valve
surgery or combined CABG and valve surgery between
2010 and 2013 was n = 11,150, of which 57% (n = 6359)
were CABG procedures, 28% (n = 3146) valve procedures
and 15% (n = 1645) combined CABG and valve proce-
dures. The majority of valve procedures were aortic valve
replacements (n = 2778, 52%), followed by mitral valve
repairs (n = 1013, 19%), multiple valve repairs (n = 969,
17%) and other (n = 624, 12%).
There were significant differences between the hospi-
tals in the following: patients’ gender (p < 0.001), age
(p = 0.019), preoperative Hb values (p < 0.001), lowest
intraoperative Hb values (p < 0.001), discharge Hb values
(p < 0.001), 24-hour blood loss (p < 0.001), and total and
postoperative stay in hospital (p < 0.001 and p = 0.001,
respectively) (Table 1).
Transfusion rates
Between 2010 and 2013 the overall transfusion rate of pa-
tients undergoing CABG surgery, valve surgery or com-
bined CABG and valve surgery was 56.9%. The trend
of the transfusion rate between 2010 and 2013 for CABG
surgery, valve surgery and CABG + valve surgery is shown
in Fig. 1. When stratified by type of surgery, the transfusion
rate in CABG surgery ranged between 43 and 54%, in valve
surgery between 54 and 67%, and in combined CABG and
valve surgery between 80 and 88%.
In hospitals A and B the transfusion percentage de-
creased significantly for all surgical procedures over time
(CABG: p < 0.001, valve: p’s < 0.001, CABG + valve:
p’s  0.02, in both hospitals). In hospital C the transfusion
rate for CABG surgery (p = 0.03) and combined CABG and
valve surgery (p = 0.006) decreased significantly, while the
transfusion rate of valve surgery did not (p = 0.26). In hos-
pital D there was no significant decrease in the transfusion
rate of CABG (p = 0.79), valve (p = 0.74), and combined
CABG and valve surgery (p = 0.12).
Predictors of blood transfusion
Multivariate logistic regression analyses were performed
to examine the predictors of blood transfusion. The site
























Fig. 1 Trend in transfusion rate of between 2010 and 2013 (CABG,
valve surgeries and combined CABG + valve surgeries) (CABG coro-
nary artery bypass graft)
(hospital B vs. hospital A, OR = 0.43; CI = 0.37–0.50,
p < 0.001; hospital C vs. hospital A, OR = 0.27; CI =
0.22–0.33, p < 0.001; hospital D vs. hospital A, OR =
0.16; CI = 0.14–0.19, p < 0.001), female gender (OR =
2.73; CI = 2.40–3.10, p < 0.001), age (OR = 1.08; CI =
1.01–1.10, p < 0.001), duration of hospitalisation (OR =
1.09; CI = 1.08–1.12, p < 0.001), preoperative Hb value
(OR = 0.57; CI = 0.54–0.60, p < 0.001), blood loss at
24 h (OR = 1.01; CI = 1.00–1.02, p < 0.001), and type of
surgery (valve (OR = 1.86; CI = 1.64–2.11, p < 0.001);
and combined CABG and valve surgery, OR = 2.96; CI =
2.47–3.55, p < 0.001) were all significantly associated with
the risk of receiving a transfusion (p’s < 0.001). These
variables explained 44% of the model variance.
Blood product use
There were significant differences between the hospitals in
the median number of transfused units of RBC, FFP and
platelets per patient in CABG, valve surgery or combined
CABG and valve surgery (p < 0.001, p = 0.001 and p =
0.023, respectively). Combining all types of surgery, the
majority of patients (47%) received at least one transfusion
with RBCs, 16% received more than two units, and only
8% received more than four units. For FFP and platelets,
33% and 10% of the patients received at least one unit, and
8% and 1% more than two units, respectively.
Combinations of transfused blood products
In CABG surgery, the main differences between the hos-
pitals were in patients receiving RBCs only, ranging from
Fig. 2 Relative number of patients with transfused RBCs, FFP,
platelets or combination of these type of blood products in CABG
surgery (CABG coronary artery bypass graft, RBC red blood cells,
FFP fresh frozen plasma, PLT platelets)
26.2% (hospital A) to 47.5% (hospital B), and a combi-
nation of RBCs, FFP and platelets, ranging from 16.8%
(hospital B) to 33.1% (hospital A) (panel A) (Fig. 2). In
valve surgery there is a large discrepancy between the use
of RBCs between hospital A (9%) and hospital C (29.6%)
(panel B) (Fig. 3). Combined CABG and valve surgery
shows a similar pattern when compared with CABG surgery
and is also associated with more hospital-specific combina-
tions of RBCs, FFP and platelets (panel C) (Fig. 4). The
proportion of transfused blood product combinations re-
mained similar between 2010 and 2013 for each hospital
(not shown).
Costs of blood transfusion
Between 2010 and 2013 the mean costs per patient between
the hospitals ranged from C 174 to C 827 for RBCs, C 49
to C 374 for FFPs, C 156 to C 550 for platelets (Table 2).
The mean costs for the total use of RBCs, FFP and platelets
combined per patient ranged between C 407 (hospital D) to
C 1673 (hospital C). The maximum cost difference per car-
diothoracic surgical procedure was C 291 (C 698 – C 407)
for CABG, C 459 (C 1131 – C 672) for valve surgery,
and C 312 (C 1673 – C 1361) for CABG combined with
valve, which corresponds to a maximum cost difference of
42% per CABG surgery and valve surgery, and 19% for
combined CABG and valve surgery. When examining the
change in costs per hospital over time, hospitals A and B
show a significant reduction in the total costs (RBC, FFP
and platelet) for CABG, valve and combined CABG and
valve surgery (p’s < 0.002) between 2010 and 2013. Hos-
pitals C and D did not show a decrease in total costs for
Neth Heart J (2017) 25:207–214 211
Fig. 3 Relative number of patients with transfused RBCs, FFP,
platelets or combination of these type of blood products in valve
surgery (RBC red blood cells, FFP fresh frozen plasma, PLT platelets)
CABG, valve and combined CABG and valve surgery over
time (p = 0.14 and p = 0.60, respectively).
Discussion
The results of this study indicate that there are substantial
differences between the hospitals in the relative number
of patients receiving a blood transfusion. With the excep-
tion of one hospital, the trend in transfusion rate showed
a decrease over time for all types of surgery. Although
we cannot assume a direct causal relationship between the
benchmark study and this decrease in transfusion rate, it
seems plausible that the benchmark helped in creating more
awareness on transfusion practices, and motivated hospitals
to initiate strategies to improve transfusion practices. Op-
timisation of blood transfusion was achieved by the use
of cell saver, continuous availability of thromboelastome-
try (ROTEM, TEM Systems Inc.), protamine management,
prevention of haemodilution, fibrinogen concentrates and
prothrombin complex concentrates, intravenous administra-
tion of iron preoperatively in patients with iron deficiency
anaemia, and careful haemostasis. These strategies were
implemented in all four hospitals. In addition, hospital A
stated it used perioperative normothermia and has a strong
focus on optimising surgical technique to prevent blood
loss. Hospital B used retrograde autologous priming of the
bypass circuit and focused on optimising the transfer from
the operating room to the intensive care unit.
This study identified differences between hospitals in so-
ciodemographic and clinical parameters, such as age, gen-
der, perioperative and postoperative Hb and blood loss. The
exact reasons for these differences are unknown. Also in
Fig. 4 Relative number of patients with transfused RBCs, FFP, PLTs
or combination of these type of blood products in CABG combined
with valve surgery (CABG coronary artery bypass graft, RBC red blood
cells, FFP fresh frozen plasma, PLT platelets)
the literature the difference in blood loss between hospitals
remains largely unexplained, irrespective of differences in
the measurement of blood loss or patient characteristics
[8]. Vonk et al. stated that a decrease in postoperative
blood loss in a hospital was probably due to the introduc-
tion of cell salvage [9]. Although a difference in the timing
of implementation of cell salvage between individual hos-
pitals could explain the difference in blood loss, it seems
more likely that the differences are the result of perioper-
ative blood management (protocols, logistical differences,
higher tolerance of blood loss to prevent clotting compli-
cations, use of alternatives for FFP). In relation to Hb, we
know that hospitals C and D accepted a lower perioperative
Hb and a lower postoperative discharge Hb than hospitals A
and B, resulting in a higher transfusion threshold. The latter
strengthens the idea that there is a need for more consensus
on the appropriate Hb transfusion threshold.
This study also showed hospital-specific transfusion
practices such as the use of hospital-specific transfused
combinations and the number of RBC, FFP and platelet
units used per patient. The percentage of patients receiving
at least one, two and four units of RBCs was slightly lower
in comparison with previous findings [10, 11]. Hospital-
specific transfusion practices were also identified in previ-
ous studies [12, 13]. An explanation for this finding could
be a difference in transfusion behaviour, in which the like-
lihood of receiving a blood transfusion is more associated
with the physician’s tolerance level of anaemia than with
the patient’s actual physiological need for correction of
the anaemia [14]. This could lead to inconsistent trans-
fusion practices and even inappropriate transfusions [15].
Alternatively, the hospital-specific transfusion practices we
identified could also be related to the difference in patient
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Table 2 Costs (in Euros) of blood products per operation category (2010–2013)a
Variables Hospital A Hospital B Hospital C Hospital D p-value
Total costs
2010–2013
C 1.949.550 C 1.938.883 C 2.328.219 C 2.380.796
Mean costs per surgeryb
RBCs
CABG 282 (252–311) 252 (221–284) 335 (305–366) 174 (158–190) <0.001
Valve 362 (299–424) 495 (410–579) 519 (449–590) 313 (274–353) <0.001
CABG & valve 700 (586–814) 751 (633–840) 827 (712–942) 679 (611–784) 0.22
FFP
CABG 120 (107–133) 49 (41–58) 129 (112–147) 68 (60–76) <0.001
Valve 201 (172–229) 118 (87–148) 297 (238–355) 148 (129–167) <0.001
CABG & valve 342 (296–388) 177 (134–220) 374 (314–434) 286 (255–317) <0.001
PLTs
CABG 242 (221–262) 156 (136–176) 234 (210–257) 165 (150–179) <0.001
Valve 319 (293–354) 300 (259–340) 315 (265–366) 210 (180–241) <0.001
CABG & valve 550 (489–612) 432 (382–482) 472 (394–550) 483 (436–530) <0.001
RBCs, FFP and PLTs
CABG 644 (589–698) 458 (405–511) 698 (638–759) 407 (376–438) <0.001
Valve 881 (769–993) 912 (768–1056) 1131 (969–1293) 672 (590–754) <0.001
CABG & valve 1593 (1397–1789) 1361 (1171–1551) 1673 (1438–1908) 1448 (1324–1572) 0.08
aData are reported as mean (95% CI) euros calculated on total study population (both transfused and non-transfused patients), costs indicated in
bold are the lowest costs for that group for all hospitals
bThe costs of blood products are based on the average cost prizes per unit of Sanquin Blood Supply between 2010–2013 (Amsterdam, the Nether-
lands), which were C 213.50 for RBCs, C 183.35 for FFP and C 511.25 for PLTs
CABG coronary artery bypass graft, RBC red blood cells, FFP fresh frozen plasma, PLT platelets
mix between academic and top clinical hospitals, or due
to the fact that there is no clear consensus on transfusion
triggers between hospitals [16–18].
In this study we also examined the costs associated with
the use of blood products in CABG, valve surgery and
combined CABG and valve surgery. This study indicates
that improving transfusion practices may result in consid-
erable cost reduction. This is important as these financial
resources can then be used to improve other aspects of pa-
tient care.
Limitations
The results of the current study should be interpreted with
the following limitations in mind. Despite our efforts to se-
lect homogenous samples of cardiac surgery patients there
were still significant differences in demographic and sur-
gical characteristics of the patients between the hospitals.
These differences could have affected transfusion rates.
Then again, we found a similar trend between the trans-
fusion rate and increasing age, and between the transfusion
rate and men vs. women (higher transfusion rate in women)
between hospitals, meaning that these differences are un-
likely to be responsible for the differences in transfusion
behaviour. In addition, we were not able to correct for
other differences in patient mix such as disease severity
(i. e. EuroScore) and comorbidity. Also, this study did not
collect information on possible wastage of blood products
after the products had been issued from the blood transfu-
sion laboratory, and on the use of alternatives for FFP, such
as fibrinogen concentrate, recombinant factor VIIa (Novo-
Seven, Novo Nordisk Inc.) and 4-factor prothrombin com-
plex. Finally, our study did not link the use of transfused
blood products to the health outcomes of the patients, such
as number of re-operations and survival after surgery. How-
ever, other studies have shown that blood transfusion is as-
sociated with increased risk of morbidity and mortality [2,
18, 19].
Recommendations
To successfully change transfusion practices it is crucial that
there is initiative and commitment, not only by the depart-
ment of cardiothoracic surgery but also by other disciplines
involved in administering or handling blood products for
transfusion. Such improvement strategies could include au-
dits, multidisciplinary consensus meetings on blood trans-
fusion practices, or the provision of insight into the use of
blood products by the individual clinician [20]. Another im-
provement strategy to reduce the number of units of RBCs
is the introduction of a new logistical policy of blood trans-
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fusion in which no elective RBC units are preoperatively
ordered [21, 22].
In addition, by benchmarking with other hospitals, hos-
pitals can share their experience and exchange ideas for
improving the standardisation and frequency of blood trans-
fusions. In order to further fine tune the transfusion prac-
tices in hospitals, it is also important to directly link blood
transfusion practices to clinical outcomes in order to de-
tect if changes in transfusion practices actually improve
survival. Finally, further research is warranted to unravel
the explanatory factors underlying the variation in use of
blood products by gaining more insight into hospital-spe-
cific transfusion triggers, the transfusion triggers for each
blood product, and by taking into account more variables
related to patient characteristics and clinical data. Also,
to attain a complete overview of current blood transfusion
practices, it is important to expand benchmarking studies
across more hospitals around the country, and to carefully
monitor improvements or deteriorations in each hospital.
Conclusion
Benchmarking transfusion practices seems to be an effec-
tive way to improve awareness and increase the standardi-
sation of transfusion practices in cardiac surgery. In addi-
tion, this study indicates that there are significant discrepan-
cies in transfusion rates, the use of specific blood products,
and in costs associated with CABG, valve, and combined
CABG and valve surgery, which seem to decrease over
time.
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